2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Rigosertib: new trials by email Literature Review of Rigosertib trials Research Report on Rigosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Rigosertib, Pembrolizumab, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 7 | 2023-05-09 | 2026-09-16 |
| Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Rigosertib, Questionnaire - Leukemia, Myelofibrosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2017-08-16 | 2020-08-07 |
Anemia (1) · Leukemia (1) · Melanoma (1) · Primary Myelofibrosis (1) · Splenomegaly (1)
M.D. Anderson Cancer Center (1) · Vanderbilt-Ingram Cancer Center (1)
United States (2)
Douglas Johnson, MD (1) · Jorge Cortes, MD (1)